Next-Generation SARS-CoV-2 Vaccine Platform

A novel, personalized, and self-amplifying RNA-based vaccine platform for inducing immunity against SARS-CoV-2 and its variants, featuring optimized spike and nucleocapsid proteins, nanoparticle-based adjuvants, and real-time immune response monitoring.

The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid immunogens delivered by a replication-defective adenovirus. However, this approach has limitations in terms of scalability, personalization, and adaptability to emerging variants. The new inventive concept addresses these limitations by introducing a self-amplifying RNA vaccine platform that can be tailored to individual patients and adapted to new variants.

The next-generation vaccine platform comprises a self-amplifying RNA vaccine encoding optimized spike and nucleocapsid proteins, which are designed for cell surface expression and endosomal targeting, respectively. The platform also incorporates nanoparticle-based adjuvants to enhance immunogenicity. Additionally, the system features real-time immune response monitoring, enabling personalized adjustments to the vaccine composition. This approach enables rapid adaptation to emerging variants and provides a scalable solution for global vaccine distribution.

The new inventive concept introduces several novel features, including the use of self-amplifying RNA vaccines, optimized spike and nucleocapsid proteins, nanoparticle-based adjuvants, and real-time immune response monitoring. These features provide a significant improvement over the original patent and enable a more effective and adaptable response to the SARS-CoV-2 pandemic.

Alternative embodiments of the inventive concept could include the use of different RNA vaccine formats, such as mRNA or saRNA, or the incorporation of additional immunogens, such as membrane protein or envelope protein. Variations could also include the use of different adjuvants or delivery methods, such as intramuscular injection or oral administration.

The next-generation SARS-CoV-2 vaccine platform has significant commercial potential in the global vaccine market, which is projected to reach $64 billion by 2027. The platform's adaptability to emerging variants and ability to provide personalized immunity make it an attractive solution for governments, healthcare organizations, and pharmaceutical companies seeking to combat the ongoing pandemic.